SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH. all-trans-Retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997; 337: 1021.
  • 2
    Tallman MS. Therapy of acute promyelocytic leukemia: all-trans-retinoic acid and beyond. Leukemia 1998; 12 (Suppl 1): S37.
  • 3
    Estey E, Thall PF, Pierce S, Kantarjian H, Keating M. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J Clin Oncol 1997; 15: 483.
  • 4
    Hiorns LR, Swansbury GJ, Mehta J, Min T, Dainton MG, Treleaven J, Powles RL, Catovsky D. Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukemia. Br J Haematol 1997; 96: 314.
  • 5
    Huang W, Sun GL, Li XS, Cao Q, Lu Y, Jang GS, Zhang FQ, Chai JR, Wang ZY, Waxman S, Chen Z, Chen SJ. Acute promyelocytic leukemia: clinical relevance of two major PML-RARα isoform and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse. Blood 1993; 82: 1264.
  • 6
    Vahdat L, Maslak P, Miller WH Jr, Eardley A, Heller G, Scheinberg DA, Warrell RP Jr. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PML-RAR-γ isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 1994; 84: 3843.
  • 7
    Slack JL, Arthur DC, Lawrence D, Mrozek K, Mayer RJ, Davey FR, Tantravahi R, Pettenati MJ, Binger S, Carroll AJ, Rao KW, Schiffer CA, Bloomfield CD. Secondary cytogenetic changes in acute promyelocytic leukemia: prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene—a Cancer and Leukemia Group B study. J Clin Oncol 1997; 15: 1786.
  • 8
    Murray CK, Estey E, Paietta E, Howard RS, Edenfield WJ, Pierce S, Mann KP, Bolan C, Byrd JC. CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome? J Clin Oncol 1999; 17: 293.
  • 9
    Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British cooperative group. Ann Intern Med 1985; 33: 451.
  • 10
    Baer MR, Stewart CC, Lawrence D, Arthur DC, Byrd JC, Davey FR, Schiffer CA, Bloomfield CD. Expression of the neural adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Blood 1997; 90: 1643.
  • 11
    Byrd JC, Weiss RB, Arthur DC, Lawrence D, Baer MR, Davey F, Trikha ES, Carroll AJ, Tantravahi R, Qumsiyeh M, Patil SR, Moore JO, Mayer RJ, Schiffer CA, Bloomfield CD. Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461. J Clin Oncol 1997; 15: 466.
  • 12
    Drach D, Zhao S, Drach J, Mahadevia R, Gattringer C, Huber H, Andreeff M. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 1992; 80: 2729.
  • 13
    Klimecki WT, Futscher BW, Grogan TM, Dalton WS. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994; 83: 2451.
  • 14
    Daniels JT, Davis BJ, Houde-McGrail L, Byrd JC. Clonal selection of CD56+ t(8;21) AML blasts: further suggestion of the adverse clinical significance of this biological marker? Br J Hematol 1999; 107: 381.
  • 15
    Ito S, Ishida Y, Murai K, Kuriya S. Flow cytometric analysis of aberrant antigen expression of blasts using CD45 blast gating fominimal residual disease in acute leukemia and high-risk myelodysplastic syndrome. Leuk Res 2001; 25: 205.
  • 16
    Guglielmi C, Martelli MP, Diverio D, Fenu S, Vegna ML, Cantu-Rajnoldi A, Biondi A, Cocito MG, Vecchio LD, Tabilio A, Avvisati G, Basso G, Coco FL. Immunophenotype of adult and childhood acute promyelocytic leukemia: correlation with morphology, type of PML gene breakpoint and clinical outcome. A cooperative Italian study on 196 cases. Br J Hematol 1998; 102: 1035.
  • 17
    Edwards RH, Wasik MA, Finan J, Rodriguez R, Moore J, Kamoun M, Rennert H, Bird J, Nowell PC, Salhany KE. Evidence for early hematopoietic progenitor cell involvement in acute promyelocytic leukemia. Am J Clin Pathol 1999; 112: 819.
  • 18
    Chaplain G, Milan C, Sgro C, Carli PM, Bonithon-Kopp C. Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: a population-based study. J Clin Oncol 2000; 18: 2836.
  • 19
    Carli PM, Sgro C, Parchin-Geneste N, Isambert N, Mugneret F, Girodon F, Maynadie M: Increased therapy-related leukemia secondary to breast cancer. Leukemia 2000; 14: 1014.
  • 20
    Hoffmann L, Moller P, Pedersen-Bjergaard J, Waage A, Pedersen M, Hirsch FR. Therapy-related acute promyelocytic leukemia with t(15;17)(q22;q12) following chemotherapy with drugs targeting DNA topoisomerase II. A report of two cases and a review of the literature: Ann Oncol 1995; 6: 781.
  • 21
    Berger R, Le Conait M, Derre J, Vecchione D, Jonveaux P. Cytogenetic studies in acute promyelocytic leukemia: a survey of secondary chromasomal abnormalities. Genes Chromosome Cancer 1991; 3: 332.
  • 22
    Sessarego M, Fugazza G, Balleari E, Bruzzone R, Ballestrero A, Patrone F. High frequency of trisomy 8 in acute promyelocytic leukemia: a fluorescence in situ hybridization study. Cancer Genet Cytogenet 1997; 97: 161.
  • 23
    Stone RM, Mayer RJ. The unique aspects of acute promyelocytic leukemia. J Clin Oncol 1990; 8: 1913.
  • 24
    Warrell RP Jr, de The H, Wang ZY, Degos L. Acute promyelocytic leukemia. N Engl J Med 1993; 329: 177.
  • 25
    Grignani F, Fagioli MF, Alcalay M, Longo L, Pandolfi PP, Donti E, Biondi A, Coco FL, Grignani F, Pelicci PG. Acute promyelocytic leukemia: from genetics to treatment. Blood 1994; 83: 10.
  • 26
    Yamada K, Furusawa S, Saito K, Waga K, Koike T, Arimura H, Aoyagi A, Yamato H, Tsunogake S, Yoshida M, Aoyagi M, Nakamura Y, Enokihara H, Tanaka K, Nakazawa K, Shishido H. Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study. Leukemia 1995; 9: 10.
  • 27
    Katayama N, Kita K, Kawakami K, Mitani H, Sugawara T, Mizuno S, Yonezawa A, Nishii K, Miwa H, Wada H, Minami N, Shiku H. Granulocyte colony-stimulating factor and its receptor in acute promyelocytic leukemia. Am J Hematol 1998; 58: 31.